Clinical effect of Azithromycin combined with Methylprednisolone in the treatment of severe mycoplasma pneumonia in children
Objective To investigate the clinical effect of Azithromycin combined with Methylprednisolone in the treatment of severe mycoplasma pneumonia in children.Methods A total of 119 children with severe mycoplasma pneumoniae pneu-monia admitted to Wuxi Children's Hospital from October 2022 to October 2023 were selected as the research objects,and they were divided into monotherapy group(n=59)and combination group(n=60)according to random number table method.The monotherapy group was treated with Azithromycin alone,and the combination group was treated with Methylpred-nisolone on the basis of monotherapy group.The clinical efficacy,duration of remission of clinical symptoms,inflammatory response and immune indexes were compared between the two groups.Results After treatment,the levels of interferon-γ(IFN-γ),interleukin-17(IL-17),interleukin-6(IL-6)and CD8+in two groups were lower than those before treatment,and the levels of immunoglobulin G(IgG),immunoglobulin A(IgA)and CD4+were higher than those before treatment,IFN-γ,IL-17,IL-6 and CD8+in combination group after treatment were lower than those in monotherapy group,IgG,IgA,CD4+levels and total clinical effective rate were higher than those in monotherapy group,and the disappearance time of cough and sputum sound,dry and wet rale and asthma were shorter than those in monotherapy group,the differences were statistically significant(P＜0.05).Conclusion Compared with single drug therapy,Azithromycin combined with Methylprednisolone is more feasible in the selection of treatment for children with severe mycoplasma pneumoniae pneumonia,and it has better improvement effects in shortening the time of clinical symptom remission,reducing inflammatory response and improving immune function.
Severe pneumoniaMycoplasma pneumoniaInflammatory responseImmune index
万方数据
维普
